首页/数据集/HDAC6 promotes Osimertinib resistant evolution in non-small cell lung cancer by activating EGFR degradation through Ubiquitin-proteasome pathway

HDAC6 promotes Osimertinib resistant evolution in non-small cell lung cancer by activating EGFR degradation through Ubiquitin-proteasome pathway

NIAID Data Ecosystem2026-05-02 收录

肿瘤耐药机制

EGFR降解

数据链接：

https://doi.org/10.7910/DVN/4SBXNL 数据链接链接失效反馈

官方服务：

资源简介：

Raw data of manuscript and supplementary materials

应用场景：

创建时间：

2025-08-24

肿瘤耐药机制

靶向药物组合

Fifty percent of cutaneous melanomas are driven by activated BRAFV600E, but tumors treated with RAF inhibitors, even when they respond dramatically, rapidly adapt and develop resistance. Thus, there i

DataONE2020-06-24 更新90

MiRNA expression data from TMZ-resistant GBM cell line

肿瘤耐药机制

miRNA表达谱

Glioblastoma multiforme(GBM) is the most common and lethal malignant primary brain tumor. Temozolomide (TMZ) is a promising chemo-therapeutic agent to treat GBM. However, resistance to TMZ develops qu

NIAID Data Ecosystem80

Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway

肿瘤耐药机制

信号通路靶向治疗

BackgroundThe sustained clinical activity of the BRAF inhibitor vemurafenib (PLX4032/RG7204) in patients with BRAFV600 mutant melanoma is limited primarily by the development of acquired resistance le

Figshare2016-01-18 更新50

Gene expression profiling in carmustine-resistant melanoma A2058 cells

肿瘤耐药机制

基因表达谱分析

Analysis of gene expression and compare the significant changed genes with associated phenotypes. Total RNA extracted from parental or carmustine-resistant A2058 cells.

NIAID Data Ecosystem80

AZ1366: An inhibitor of tankyrase and the canonical Wnt pathway that limits the persistence of non-small cell lung cancer cells following EGFR inhibition. Homo sapiens

肿瘤耐药机制

组合治疗

EGFR-mut NSCLC lines show differential suceptibility to inhibition of tankyrase in the presence of EGFR inhibitors Overall design: NSCLC cells were treated in quadruplicate with gefitinib, AZ1366 (tan

NIAID Data Ecosystem80

HDAC6 promotes Osimertinib resistant evolution in non-small cell lung cancer by activating EGFR degradation through Ubiquitin-proteasome pathway

资源简介：

相关数据集